UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8‑K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
March 8, 2017
IRIDEX CORPORATION
(Exact name of registrant as specified in its charter)
|
Delaware |
0-27598 |
77-0210467 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
1212 Terra Bella Avenue
Mountain View, California 94043
(Address of principal executive offices, including zip code)
(650) 940-4700
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On March 8, 2017, IRIDEX Corporation issued a press release discussing revenues for its fourth fiscal quarter of 2016, which ended December 31, 2016. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
(d) |
Exhibits |
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release dated March 8, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
IRIDEX CORPORATION |
|
|
|
|
|
By: |
|
/s/ WILLIAM M. MOORE |
|
|
|
William M. Moore President and Chief Executive Officer |
Date: March 8, 2017
EXHIBIT INDEX
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release dated March 8, 2017. |
Exhibit 99.1
IRIDEX Announces Fourth Quarter and 2016 Financial Results
and Provides Full Year 2017 Financial Outlook
Cyclo G6™ Glaucoma Laser Platform Fourth Quarter Revenue Up 67% Year-over-Year
Record Revenue of $12.5 Million in the Fourth Quarter of 2016
MOUNTAIN VIEW, Calif., March 8, 2017 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the three months and full year ended December 31, 2016 and provided its full year 2017 financial outlook.
Fourth Quarter and 2016 Financial Highlights
|
|
• |
Total revenue of $12.5 million for the fourth quarter of 2016, a 3.4% increase year over year. Full year total revenue of $46.2 million, an increase of 10.5% compared to full year 2015. |
|
|
• |
Cyclo G6™ glaucoma laser platform revenues in the fourth quarter of 2016 increased 67% year over year with a full year 2016 increase of 311% compared to full year 2015. |
Recent Business Highlights
|
|
• |
Sold 96 Cyclo G6 systems and shipped approximately 8,000 G6 probes in the fourth quarter of 2016, bringing the total for the full year 2016 to 384 and 27,000, respectively. |
|
|
• |
Increased U.S. sales organization to 17 direct sales representatives and added one Area Sales Manager. |
|
|
• |
Established Iridex GmbH to facilitate a direct sales initiative in Germany. |
|
|
• |
Commercially launched G-Probe™ Illuminate at the American Glaucoma Society (AGS) Annual Meeting. The G-Probe Illuminate has built-in transillumination that optimizes placement of the probe and therapeutic outcomes in the treatment of glaucoma. The G-Probe Illuminate is the third disposable probe designed for use with the Cyclo G6 system. |
|
|
• |
Conducted live surgery webcast at the Asia-Pacific Academy of Ophthalmology (APAO) meeting in Singapore. |
“We are pleased that 2016 was a strong year for Iridex, marked by the continued growth of our Cyclo G6 system for the treatment of glaucoma. During the year, we expanded both system placements and disposable probe utilization, broadened our platform offering, achieved compelling clinical outcomes, and continued to increase our global presence,” stated William M. Moore, President and CEO. “The Cyclo G6 is rapidly transforming our business and continues to outperform our expectations. I believe we have only just begun to see the potential of what our MicroPulse® technology can do for the treatment of eye disease.”
Fourth Quarter 2016 Financial Results
Revenue for the three months ended December 31, 2016 increased 3.4% to $12.5 million from $12.1 million during the same period of the prior year. Growth in revenue was primarily driven by an increase in sales of the Cyclo G6 glaucoma laser platform which was partially offset by lower surgical retina product revenue.
Gross profit for the fourth quarter of 2016 was $5.6 million, or 44.4% gross margin, compared to $5.5 million, or 45.3% gross margin, in the same period of the prior year. Gross margins are expected to continue to fluctuate due to a variety of factors including changes in the mix of domestic and international sales, product mix, and manufacturing variances.
Operating expenses for the fourth quarter of 2016 were $6.6 million compared to $5.0 million in the same period of the prior year. The increase was largely due to investments to support the Company's commercial infrastructure, including increased sales and marketing, and quality and regulatory expenses.
Loss from operations for the fourth quarter of 2016 was $1.1 million, compared to income from operations of $0.5 million for the same period of the prior year.
In the fourth quarter of 2016, the Company recorded a full valuation allowance against all its deferred tax assets and recorded a non-cash provision for income taxes of $9.7 million. This valuation allowance contributed to our net loss for the fourth quarter of 2016 of $10.8 million, compared to net income of $0.4 million in the prior year.
Full Year 2016 Financial Results
Revenue for the year ended December 31, 2016 increased 10.5% to $46.2 million, from $41.8 million in 2015. Growth in revenue was primarily driven by an increase in sales of the Cyclo G6 glaucoma laser platform which was partially offset by lower surgical and medical retina product revenue.
Gross profit for the year was $20.8 million, or 45.1% gross margin, up from $20.0 million, or 47.8% gross margin, for the prior year. The decrease in gross margin was attributable primarily to a shift in geographic and product mix and manufacturing variances.
Operating expenses for 2016 were $23.4 million compared to $19.7 million in the prior year. Operating expenses increased largely due to investments to support the Company’s commercial infrastructure including sales and marketing and quality and regulatory expenses, as well as an increase in severance costs and non-cash stock-based compensation.
In 2016, the Company recorded a full valuation allowance against all its deferred tax assets and recorded a non-cash provision for income taxes of $9.1 million in 2016. This valuation allowance contributed to our net loss for 2016 of $11.7 million, compared to net income of $0.5 million in the prior year.
Cash and cash equivalents were $23.7 million as of December 31, 2016.
IRIDEX projects revenue for the full year 2017 to be $48 to $52 million, driven by growth in the Company’s Cyclo G6 glaucoma laser platform. The Company anticipates that in 2017, it will sell 400 to 450 Cyclo G6 laser systems and ship 45,000 to 50,000 G6 probes. In 2017, we anticipate revenue growth to be more heavily weighted towards the second half of the year as we start to see the full benefits of our growth investments.
Webcast and Conference Call Information
IRIDEX’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 61156151. A live and archived webcast of the event will be available on the “Investor Relations” section of the Company’s website at: www.iridex.com. A telephone replay will also be available beginning Wednesday, March 8, 2017 through Thursday, March 9, 2017 by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers, using conference ID: 61156151.
About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning revenue and Cyclo G6 projections for fiscal 2017, future demand and order levels for the Company's products, future operating expenses, changes in personnel, product development and intellectual property related matters, the adoption and effect of Company products on its results, the markets in which the Company operates, usage and efficacy of the Company's products, the Company’s future financial results, and the Company's strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 2, 2016, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
investors@iridex.com
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(unaudited)
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
|||||||||||
|
|
December 31, |
|
|
January 2, |
|
|
December 31, |
|
|
January 2, |
|
||||||
|
|
|
2016 |
|
|
2016 |
|
|
2016 |
|
|
2016 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
$ |
12,530 |
|
|
$ |
12,113 |
|
|
$ |
46,158 |
|
|
$ |
41,757 |
|
|
|
Cost of revenues |
|
|
6,967 |
|
|
|
6,628 |
|
|
|
25,319 |
|
|
|
21,804 |
|
|
|
Gross profit |
|
|
5,563 |
|
|
|
5,485 |
|
|
|
20,839 |
|
|
|
19,953 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
1,358 |
|
|
|
1,214 |
|
|
|
5,365 |
|
|
|
5,214 |
|
|
|
Sales and marketing |
|
|
3,069 |
|
|
|
2,438 |
|
|
|
10,281 |
|
|
|
8,901 |
|
|
|
General and administrative |
|
|
2,092 |
|
|
|
1,344 |
|
|
|
7,638 |
|
|
|
5,550 |
|
|
|
Impairment of intangible assets |
|
|
120 |
|
|
|
- |
|
|
|
120 |
|
|
|
- |
|
|
|
Total operating expenses |
|
|
6,639 |
|
|
|
4,996 |
|
|
|
23,404 |
|
|
|
19,665 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from operations |
|
|
(1,076 |
) |
|
|
489 |
|
|
|
(2,565 |
|
) |
|
288 |
|
|
|
Other (expense) income, net |
|
|
(8 |
) |
|
|
(131 |
) |
|
|
(91 |
|
) |
|
3 |
|
|
|
(Loss) income from operations before provision for (benefit from) income taxes |
|
|
(1,084 |
) |
|
|
358 |
|
|
|
(2,656 |
|
) |
|
291 |
|
|
|
Provision for (benefit from) income taxes |
|
|
9,731 |
|
|
|
(80 |
) |
|
|
9,057 |
|
|
|
(183 |
) |
|
|
Net (loss) income |
|
$ |
(10,815 |
) |
|
$ |
438 |
|
|
$ |
(11,713 |
|
) |
$ |
474 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(1.04 |
) |
|
$ |
0.04 |
|
|
$ |
(1.15 |
|
) |
$ |
0.05 |
|
|
|
Diluted |
|
$ |
(1.04 |
) |
|
$ |
0.04 |
|
|
$ |
(1.15 |
|
) |
$ |
0.05 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net (loss) income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
10,443 |
|
|
|
9,980 |
|
|
|
10,173 |
|
|
|
9,962 |
|
|
|
Diluted |
|
|
10,443 |
|
|
|
10,086 |
|
|
|
10,173 |
|
|
|
10,128 |
|
|
|
|
Condensed Consolidated Balance Sheets
(In thousands and unaudited)
|
|
|
December 31, |
|
|
January 2, |
|
||
|
|
|
2016 |
|
|
2016 |
|
||
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
23,747 |
|
|
$ |
9,995 |
|
|
Accounts receivable, net |
|
|
10,025 |
|
|
|
9,282 |
|
|
Inventories |
|
|
11,643 |
|
|
|
11,106 |
|
|
Prepaids and other current assets |
|
|
450 |
|
|
|
386 |
|
|
Total current assets |
|
|
45,865 |
|
|
|
30,769 |
|
|
Property and equipment, net |
|
|
1,534 |
|
|
|
1,104 |
|
|
Intangible assets, net |
|
|
132 |
|
|
|
268 |
|
|
Goodwill |
|
|
533 |
|
|
|
533 |
|
|
Deferred income taxes-long term |
|
|
- |
|
|
|
8,985 |
|
|
Other long-term assets |
|
|
80 |
|
|
|
164 |
|
|
Total assets |
|
$ |
48,144 |
|
|
$ |
41,823 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
1,994 |
|
|
$ |
2,223 |
|
|
Accrued compensation |
|
|
2,346 |
|
|
|
1,572 |
|
|
Accrued expenses |
|
|
2,135 |
|
|
|
1,722 |
|
|
Accrued warranty |
|
|
603 |
|
|
|
603 |
|
|
Deferred revenue |
|
|
1,383 |
|
|
|
1,311 |
|
|
Total current liabilities |
|
|
8,461 |
|
|
|
7,431 |
|
|
|
|
|
|
|
|
|
|
|
|
Long-Term liabilities: |
|
|
|
|
|
|
|
|
|
Other long-term liabilities |
|
|
523 |
|
|
|
704 |
|
|
Total liabilities |
|
|
8,984 |
|
|
|
8,135 |
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
|
Common stock |
|
|
124 |
|
|
|
111 |
|
|
Additional paid-in capital |
|
|
55,158 |
|
|
|
37,986 |
|
|
Accumulated deficit |
|
|
(16,122 |
) |
|
|
(4,409 |
) |
|
Total stockholders' equity |
|
|
39,160 |
|
|
|
33,688 |
|
|
|
||||||||
|
Total liabilities and stockholders' equity |
|
$ |
48,144 |
|
|
$ |
41,823 |
|